KR20240067229A - 치료학적 화합물 - Google Patents

치료학적 화합물 Download PDF

Info

Publication number
KR20240067229A
KR20240067229A KR1020247002091A KR20247002091A KR20240067229A KR 20240067229 A KR20240067229 A KR 20240067229A KR 1020247002091 A KR1020247002091 A KR 1020247002091A KR 20247002091 A KR20247002091 A KR 20247002091A KR 20240067229 A KR20240067229 A KR 20240067229A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
compound
heteroaryl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002091A
Other languages
English (en)
Korean (ko)
Inventor
아지트 케이. 파르히
이 유안
옹정 장
예수스 로사도
프라티크 다타
Original Assignee
택시스 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 택시스 파마슈티칼스, 인크. filed Critical 택시스 파마슈티칼스, 인크.
Publication of KR20240067229A publication Critical patent/KR20240067229A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247002091A 2021-06-22 2022-06-21 치료학적 화합물 Pending KR20240067229A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213519P 2021-06-22 2021-06-22
US63/213,519 2021-06-22
PCT/US2022/034374 WO2022271723A1 (en) 2021-06-22 2022-06-21 Therapeutic compounds

Publications (1)

Publication Number Publication Date
KR20240067229A true KR20240067229A (ko) 2024-05-16

Family

ID=84544904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002091A Pending KR20240067229A (ko) 2021-06-22 2022-06-21 치료학적 화합물

Country Status (10)

Country Link
US (1) US20240317749A1 (cg-RX-API-DMAC7.html)
EP (1) EP4359416A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024524213A (cg-RX-API-DMAC7.html)
KR (1) KR20240067229A (cg-RX-API-DMAC7.html)
CN (1) CN118251394A (cg-RX-API-DMAC7.html)
AU (1) AU2022297426A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225427A1 (cg-RX-API-DMAC7.html)
IL (1) IL309569A (cg-RX-API-DMAC7.html)
MX (1) MX2024000022A (cg-RX-API-DMAC7.html)
WO (1) WO2022271723A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117815240A (zh) * 2023-12-11 2024-04-05 兰州大学 一类具有二氨基吡咯并喹唑啉结构的化合物在防治奶牛乳腺炎致病菌中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436524T3 (es) * 2003-05-22 2014-01-02 Nerviano Medical Sciences S.R.L. Derivados de pirazolo-quinazolina, procedimiento para su preparación y su uso como inhibidores de cinasas
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US20090227575A1 (en) * 2008-03-04 2009-09-10 Wyeth 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
BR112013008527A2 (pt) * 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US12428423B2 (en) * 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
US11077109B2 (en) * 2017-08-01 2021-08-03 The Trustees Of Princeton University Compounds having antibacterial activity and methods of use
KR102464677B1 (ko) * 2017-08-11 2022-11-10 셍커 파마슈티컬스 (지앙수) 엘티디. 단백질 인산화효소 억제제로 작용하는 1h-피라졸로[4,3-h]퀴나졸린 화합물
CN119455003A (zh) * 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
WO2022040596A1 (en) * 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
EP4204093A1 (en) * 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors

Also Published As

Publication number Publication date
WO2022271723A1 (en) 2022-12-29
EP4359416A1 (en) 2024-05-01
AU2022297426A1 (en) 2024-02-01
MX2024000022A (es) 2024-03-15
JP2024524213A (ja) 2024-07-05
US20240317749A1 (en) 2024-09-26
CA3225427A1 (en) 2022-12-29
IL309569A (en) 2024-02-01
CN118251394A (zh) 2024-06-25
EP4359416A4 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
US9926261B2 (en) Bacterial efflux pump inhibitors
US11845742B2 (en) Therapeutic compounds and methods to treat infection
US9950993B2 (en) Bacterial efflux pump inhibitors
US11826357B2 (en) Bacterial efflux pump inhibitors
US11180459B2 (en) Bacterial efflux pump inhibitors
US11993571B2 (en) Indole derivatives as efflux pump inhibitors
US11458121B2 (en) Therapeutic compounds and methods to treat infection
DK160276B (da) 7-(3-aminosubstitueret-1-pyrrolidinyl)-1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-1,8-naphthyridin-3-carboxylsyrederivater, salte eller hydrater deraf
US20190031624A1 (en) Therapeutic compounds and methods to treat infection
US10556854B2 (en) Bacterial efflux pump inhibitors
WO2018165614A1 (en) Bacterial efflux pump inhibitors
WO2017147335A1 (en) Bacterial efflux pump inhibitors
HU194866B (en) Process for producing 7-/3-aryl-1-piperazinyl/- and 7-/3-cyclohexyl-1-piperazinyl/-3-quinoline-carboxylic acids and pharmaceutical compositions containing them as active agents
US5091384A (en) Anti-bacterial quinolone- and naphthyridone-carboxylic acid compounds
JP6411355B2 (ja) 抗菌剤
US9822108B2 (en) Antimicrobial agents
WO2022271723A1 (en) Therapeutic compounds
WO2021243273A1 (en) Bacterial efflux pump inhibitors
WO2025043115A1 (en) Bacterial efflux pump inhibitors
HK1215031B (en) Antimicrobial agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000